# AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer

> **NCT07712094** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 56 (estimated)

## Conditions studied

- Neuroendocrine Cancer

## Interventions

- **DRUG:** AK112
- **DRUG:** Irinotecan
- **DRUG:** Cisplatin
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT07712094
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2029-02-27
- **Final completion:** 2029-08-31
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07712094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07712094, "AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07712094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*